{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:20:04Z","timestamp":1794277204388,"version":"4.9.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation Project of China","doi-asserted-by":"crossref","award":["81470642"],"award-info":[{"award-number":["81470642"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation Project of China","doi-asserted-by":"crossref","award":["81800837"],"award-info":[{"award-number":["81800837"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation Project of China","doi-asserted-by":"crossref","award":["81770964"],"award-info":[{"award-number":["81770964"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12886-019-1067-4","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T08:05:10Z","timestamp":1551168310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40\u2009weeks post menstrual age: a retrospective case series study"],"prefix":"10.1186","volume":"19","author":[{"given":"Jiao","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunda","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5092-9550","authenticated-orcid":false,"given":"Peiquan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"issue":"Suppl 1","key":"1067_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/pr.2013.205","volume":"74","author":"H Blencowe","year":"2013","unstructured":"Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res. 2013;74(Suppl 1):35\u201349.","journal-title":"Pediatr Res"},{"issue":"4","key":"1067_CR2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1001\/archopht.1988.01060130509025","volume":"106","author":"W Tasman","year":"1988","unstructured":"Tasman W. Multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol. 1988;106(4):463\u20134.","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"1067_CR3","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/S0161-6420(91)32074-8","volume":"98","author":"EA Palmer","year":"1991","unstructured":"Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, Tung B. Incidence and early course of retinopathy of prematurity. The cryotherapy for retinopathy of prematurity cooperative group. Ophthalmology. 1991;98(11):1628\u201340.","journal-title":"Ophthalmology"},{"issue":"5","key":"1067_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1001\/archopht.118.5.645","volume":"118","author":"MX Repka","year":"2000","unstructured":"Repka MX, Palmer EA, Tung B. Involution of retinopathy of prematurity. Cryotherapy for retinopathy of prematurity cooperative group. Arch Ophthalmol. 2000;118(5):645\u20139.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"1067_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1542\/peds.2004-1413","volume":"116","author":"WV Good","year":"2005","unstructured":"Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Quintos M, Tung B, Early treatment for retinopathy of prematurity cooperative G. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics. 2005;116(1):15\u201323.","journal-title":"Pediatrics"},{"issue":"7","key":"1067_CR6","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1097\/IAE.0b013e31820d3f70","volume":"31","author":"LY Ho","year":"2011","unstructured":"Ho LY, Ho V, Aggarwal H, Ranchod TM, Capone A Jr, Trese MT, Drenser KA. Management of avascular peripheral retina in older prematurely born infants. Retina. 2011;31(7):1248\u201354.","journal-title":"Retina"},{"issue":"7","key":"1067_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ, Group B-RC. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603\u201315.","journal-title":"N Engl J Med"},{"issue":"6","key":"1067_CR8","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","volume":"28","author":"HA Mintz-Hittner","year":"2008","unstructured":"Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008;28(6):831\u20138.","journal-title":"Retina"},{"key":"1067_CR9","unstructured":"Mueller B, Salchow DJ, Waffenschmidt E, Joussen AM, Schmalisch G, Czernik C, Buhrer C, Schunk KU, Girschick HJ, Winterhalter S. Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Br J Ophthalmol. 2017;101(3):365-70."},{"issue":"4","key":"1067_CR10","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","volume":"37","author":"G Zhang","year":"2017","unstructured":"Zhang G, Yang M, Zeng J, Vakros G, Su K, Chen M, Li H, Tian R, Li N, Tang S, et al. Comparison of intravitreal injection of Ranibizumab versus laser therapy for zone ii treatment-requiring retinopathy of prematurity. Retina. 2017;37(4):710\u20137.","journal-title":"Retina"},{"issue":"11","key":"1067_CR11","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","volume":"92","author":"S Kusaka","year":"2008","unstructured":"Kusaka S, Shima C, Wada K, Arahori H, Shimojyo H, Sato T, Fujikado T. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol. 2008;92(11):1450\u20135.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"1067_CR12","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","volume":"35","author":"SN Chen","year":"2015","unstructured":"Chen SN, Lian I, Hwang YC, Chen YH, Chang YC, Lee KH, Chuang CC, Wu WC. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and bevacizumab. Retina. 2015;35(4):667\u201374.","journal-title":"Retina"},{"key":"1067_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2015.12.005","volume":"163","author":"MP Gupta","year":"2016","unstructured":"Gupta MP, Chan RV, Anzures R, Ostmo S, Jonas K, Chiang MF, Imaging, Informatics in ROPRC. Practice patterns in retinopathy of prematurity treatment for disease milder than recommended by guidelines. Am J Ophthalmol. 2016;163:1\u201310.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"1067_CR14","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of P","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of P. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123(7):991\u20139.","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"1067_CR15","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative G","year":"2003","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative G. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684\u201394.","journal-title":"Arch Ophthalmol"},{"issue":"26","key":"1067_CR16","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1056\/NEJMra1208129","volume":"367","author":"ME Hartnett","year":"2012","unstructured":"Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012;367(26):2515\u201326.","journal-title":"N Engl J Med"},{"issue":"2","key":"1067_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1091-8531(97)90008-2","volume":"1","author":"TL Young","year":"1997","unstructured":"Young TL, Anthony DC, Pierce E, Foley E, Smith LE. Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity. J AAPOS. 1997;1(2):105\u201310.","journal-title":"J AAPOS"},{"issue":"8","key":"1067_CR18","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.ophtha.2017.03.018","volume":"124","author":"Q Huang","year":"2017","unstructured":"Huang Q, Zhang Q, Fei P, Xu Y, Lyu J, Ji X, Peng J, Li YA, Zhao P. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors. Ophthalmology. 2017;124(8):1156\u201364.","journal-title":"Ophthalmology"},{"issue":"3","key":"1067_CR19","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1167\/iovs.16-20680","volume":"58","author":"J Lyu","year":"2017","unstructured":"Lyu J, Zhang Q, Chen CL, Xu Y, Ji XD, Li JK, Huang QJ, Zhao PQ. Recurrence of retinopathy of prematurity after intravitreal Ranibizumab monotherapy: timing and risk factors. Invest Ophthalmol Vis Sci. 2017;58(3):1719\u201325.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1067_CR20","doi-asserted-by":"crossref","unstructured":"Isaac M, Mireskandari K, Tehrani N. Does bevacizumab Alter vascularization potential in retinopathy of prematurity? Ophthalmology. 2016;123(9):2042-3.","DOI":"10.1016\/j.ophtha.2016.04.024"},{"issue":"10","key":"1067_CR21","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.ophtha.2016.06.055","volume":"123","author":"BC Toy","year":"2016","unstructured":"Toy BC, Schachar IH, Tan GS, Moshfeghi DM. Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity. Ophthalmology. 2016;123(10):2166\u201375.","journal-title":"Ophthalmology"},{"issue":"4","key":"1067_CR22","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","volume":"38","author":"JM Garcia Gonzalez","year":"2018","unstructured":"Garcia Gonzalez JM, Snyder L, Blair M, Rohr A, Shapiro M, Greenwald M. Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity. Retina. 2018;38(4):764\u201372.","journal-title":"Retina"},{"issue":"8","key":"1067_CR23","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130(8):1000\u20136.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"1067_CR24","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1097\/IAE.0000000000001685","volume":"38","author":"Y Yonekawa","year":"2018","unstructured":"Yonekawa Y, Wu WC, Nitulescu CE, Chan RVP, Thanos A, Thomas BJ, Todorich B, Drenser KA, Trese MT, Capone A Jr. Progressive retinal detachment in infants with retinopathy of prematurity treated with intravitreal bevacizumab or Ranibizumab. Retina. 2018;38(6):1079\u201383.","journal-title":"Retina"},{"issue":"9","key":"1067_CR25","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/archophthalmol.2011.229","volume":"129","author":"MX Repka","year":"2011","unstructured":"Repka MX, Tung B, Good WV, Capone A Jr, Shapiro MJ. Outcome of eyes developing retinal detachment during the early treatment for retinopathy of prematurity study. Arch Ophthalmol. 2011;129(9):1175\u20139.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"1067_CR26","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1136\/bjophthalmol-2014-305913","volume":"99","author":"Z Tan","year":"2015","unstructured":"Tan Z, Chong C, Darlow B, Dai S. Visual impairment due to retinopathy of prematurity (ROP) in New Zealand: a 22-year review. Br J Ophthalmol. 2015;99(6):801\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"1067_CR27","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/jamaophthalmol.2014.5185","volume":"133","author":"GS Ying","year":"2015","unstructured":"Ying GS, Quinn GE, Wade KC, Repka MX, Baumritter A, Daniel E, e ROPCG. Predictors for the development of referral-warranted retinopathy of prematurity in the telemedicine approaches to evaluating acute-phase retinopathy of prematurity (e-ROP) study. JAMA Ophthalmol. 2015;133(3):304\u201311.","journal-title":"JAMA Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1067-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-019-1067-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1067-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T19:18:33Z","timestamp":1582658313000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-019-1067-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,26]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1067"],"URL":"https:\/\/doi.org\/10.1186\/s12886-019-1067-4","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,26]]},"assertion":[{"value":"21 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Study protocols were in accordance with the tenets of Declaration of Helsinki and approved by the hospital ethics committee (Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine). The study and off-label use of Ranibizumab were certified by Ethics Committee of Xin hua Hospital and informed consent to participate was exempted due to retrospective nature of the study (Approval No. XHEC-D-2018-028).Written informed consent for off-label IVR treatment for ROP was obtained from legal guardians of all patients after detailed counseling regarding the potential benefits (possibly, quick regression after single injection, anterior progression of retinal vascularization, preservation of peripheral visual field) and risks (possibly, infection, hemorrhage, fibrosis, retreatment) of the treatment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"60"}}